Table 2. Comparison of developmental Beta-lactam/Beta-lactamase inhibitor combinations.
| Beta-lactam | Beta-lactamase inhibitor | Ratio | Company | Comment |
|---|---|---|---|---|
| Ceftolozane | tazobactam | 2:1 | Cubist | Active vs Pseudomonas aeruginosa |
| Ceftazidime | avibactam | 4:1 | A-Z | Active vs ESBLs |
| Ceftaroline | avibactam | 1:1 | Forest/Cerexa | Active vs ESBLs |
| Imipenem-cilastatin | MK 7655 | 2:2:1 | Merck | Active vs carbapenemase |
| Imipenem-cilastatin | MK 7655 | 4:4:1 | Merck | Active vs carbapenemase |
| Meropenem | RPX7009 | 1:1 | Rempex | Active vs class A serine carbapenemases, + Pseudomonas species |
ESBLs, extended-spectrum beta-lactamases.